

Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294)

Specifications:

Name: Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free

Description: Recombinant human monoclonal antibody to PD-L1.

Applications: ELISA, FACS, Functional Assay, In Vivo

Reactivity: Human, Mouse, Cynomolgus Macaque, Dog, Rat, Rabbit

Host: Human

Clonality: Monoclonal

Isotype: IgG1

Light Chains: lambda

Conjugate: Unconjugated

Purification: Protein A affinity chromatography.

Concentration: Reconstitution dependent.

Molecular Weight: This antibody has a predicted MW of 150 kDa.

Purity: > 95% (by SDS-PAGE and SEC-HPLC).

Product Form: Lyophilized

Reconstitution: Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml

concentration. Gently shake to solubilize completely. Do not vortex!

Formulation: Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.

Storage: Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at


-80°C. Product is stable for one year. Avoid freeze/thaw cycles.

Disclaimer: This product is for research use only. It is not intended for diagnostic or therapeutic use.




Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294)


Images:




SDS-PAGE analysis of Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294) under reducing (R) conditions confirms that the purity of this antibody is greater than 95%.



SEC-HPLC analysis of Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294) confirms that the purity of this antibody is 98.22%.



Immobilized recombinant human PD-L1 protein (Fc tag) at 2 μ g/ml is bound by Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294). EC50 = 0.03725 μ g/ml.



Avelumab Biosimilar - Anti-PD-L1 Antibody - Low endotoxin, Azide free (A323294) inhibited the tumor growth of MC38 on hLAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 32.6% at 1 mpk at D28.